Thrombosis
Conference Coverage
What 2019’s top five CAD trials tell us
SNOWMASS, COLO. – Triple therapy as a triple threat – a three-pronged threat to patient safety, Dr. Malcolm R. Bell says.
Conference Coverage
Vigilance safely keeps AFib patients off anticoagulants post ablation
NATIONAL HARBOR, MD. – One U.S. center uses frequent monitoring to allow selected AFib patients to safely stop anticoagulation after catheter...
Conference Coverage
Are providers asking about menstrual bleeding before/during anticoagulant therapy?
Conference Coverage
ENGAGE AF-TIMI: Insulin linked to greater risk for stroke, CV death, bleeding
LOS ANGELES – Use of novel oral anticoagulants may be preferred over vitamin K antagonists in patients with diabetes and AFib.
Conference Coverage
New ASH guideline: VTE prophylaxis after major surgery
ORLANDO – The chair of VTE guidelines panel presented highlights of the latest guidelines in a special session at the annual meeting of the...
Conference Coverage
Aspirin plus a DOAC may do more harm than good in some
Adding aspirin to DOAC therapy for the secondary prevention of VTE or the prevention of stroke associated with NVAF without a clear indication...
Conference Coverage
Treating LDL to below 70 reduces recurrent stroke
PHILADELPHIA – Results of TST, a rare cholesterol study in patients with a history of ischemic stroke, explore the benefits of treating to a lower...
Conference Coverage
The TWILIGHT of aspirin post-PCI for ACS?
PHILADELPHIA –
Conference Coverage
GALILEO, GALILEO 4D: Mixed results in post-TAVR anticoagulation
Conference Coverage
Thromboembolic events more likely among CIDP patients with CVAD
AUSTIN, TEX. – Although the study matched patients by demographic factors, researchers did not adjust the analysis for risk factors or confounders...
News from the FDA/CDC
FDA approves rivaroxaban for VTE prevention in hospitalized, acutely ill patients
The latest approval is based on results from the phase 3 MAGELLAN and MARINER trials, which included more than 20,000 patients.